Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) EBITDA (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EBITDA for 2 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 175.34% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.2 million, a N/A change, with the full-year FY2025 number at -$201103.0, up 98.7% from a year prior.
  • EBITDA was $2.4 million for Q4 2025 at Neuphoria Therapeutics, up from -$9.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $11.1 million in Q1 2025 to a low of -$9.9 million in Q3 2025.